DuPont, of Wilmington, Del., named the first five members of its external Biotechnology Advisory Panel. They are: Andre Capron, director of the Institut Pasteur de Lille in France; Arthur Caplan, director of the Bioethics Center at the University of Pennsylvania; Jonathan Lash, president of the World Resources Institute in Washington; Tiahoga Ruge, president and director of the North American Center for Environmental Information and Communication in Mexico City; and Florence Wambugu, director of the International Service for the Acquisition of Agri-biotech Applications in Nairobi, Kenya.

Eligix Inc., of Medford, Mass., appointed James Fitzgerald senior vice president, finance and operations, and chief financial officer.

EluSys Therapeutics Inc., of Pine Brook, N.J., elected to its scientific advisory board Gordon Douglas, former president of Merck Vaccines.

FeRx Inc., of San Diego, named Vicente Anido, former president and CEO of CombiChem Inc., to its board of directors,

Genencor International, of Rochester, N.Y., promoted William Lutz to vice president, global information technology.

Human Genome Sciences Inc., of Rockville, Md., named Sally Bolmer vice president, regulatory affairs.

Idec Pharmaceuticals Corp., of San Diego, named Wolfgang Berthold senior vice president of biopharmaceutical sciences.

Immunex Corp., of Seattle, named Mark Booth senior vice president and general manager for Enbrel, and Richard Stead vice president clinical development.

Invitrogen Corp., of San Diego, named Lewis Shuster chief operating officer.

Labopharm Inc., of Laval, Quebec, hired James Howard-Tripp as executive vice president.

Lexicon Genetics Inc., of The Woodlands, Texas, appointed James Piggott senior vice president of pharmaceutical biology, and Julia Gregory executive vice president and chief financial officer.

Mendel Biotechnology Inc., of Haywood, Calif., appointed David Summa president and CEO.

Neurogen Corp., of Branford, Conn., promoted Stephen Davis to senior vice president and chief business officer.

Maxygen Inc., of Redwood City, Calif., appointed to its board of directors George Poste, chief science and technology officer at SmithKline Beecham plc, of London. In addition, it named Michael Rabson general counsel and senior vice president of legal affairs and John Bedbrook president of agriculture. Howard Simon was named vice president of human resources and administration, Stuart Pollard director of protein pharmaceutical business development, and Keith Powell vice president of chemicals and core technology.